Who are Methotrexate, 6-mercaptopurine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): LCP-tacrolimus QD + MMF BID, Trifluridine and Tipiracil, Pred + Meth, Busulphan plus Fludarabine, MTX + 5-FU sequential therapy, Lomustine, intermediate dose cytarabine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/methotrexate-6-mercaptopurine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Methotrexate, 6-mercaptopurine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Methotrexate, 6-mercaptopurine (Methotrexate, 6-mercaptopurine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimetabolite combination. Area: Oncology.

phase 3 Antimetabolite combination Dihydrofolate reductase (methotrexate); hypoxanthine-guanine phosphoribosyltransferase (6-mercaptopurine) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Methotrexate, 6-mercaptopurine (Methotrexate, 6-mercaptopurine) — Children's Cancer Group, China. This combination of methotrexate and 6-mercaptopurine inhibits nucleotide synthesis and DNA replication to suppress cancer cell proliferation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Methotrexate, 6-mercaptopurine TARGET	Methotrexate, 6-mercaptopurine	Children's Cancer Group, China	phase 3	Antimetabolite combination	Dihydrofolate reductase (methotrexate); hypoxanthine-guanine phosphoribosyltransferase (6-mercaptopurine)
LCP-tacrolimus QD + MMF BID	LCP-tacrolimus QD + MMF BID	University Hospital, Limoges	marketed	Calcineurin inhibitor + antimetabolite combination	Calcineurin (tacrolimus); IMPDH type II (mycophenolate mofetil)
Trifluridine and Tipiracil	Trifluridine and Tipiracil	Amgen	marketed	Antimetabolite combination; thymidylate synthase inhibitor	Thymidylate synthase; thymidine phosphorylase
Pred + Meth	Pred + Meth	Hamad Medical Corporation	phase 3	Corticosteroid + Antimetabolite combination	Glucocorticoid receptor (prednisolone); Dihydrofolate reductase (methotrexate)
Busulphan plus Fludarabine	Busulphan plus Fludarabine	Gruppo Italiano Trapianto di Midollo Osseo	phase 3	Alkylating agent + Antimetabolite combination
MTX + 5-FU sequential therapy	MTX + 5-FU sequential therapy	Japan Clinical Oncology Group	phase 3	Antimetabolite combination chemotherapy	Thymidylate synthase, dihydrofolate reductase
Lomustine, intermediate dose cytarabine	Lomustine, intermediate dose cytarabine	French Innovative Leukemia Organisation	phase 3	Alkylating agent + nucleoside antimetabolite combination

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimetabolite combination class)

Children's Cancer Group, China · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Methotrexate, 6-mercaptopurine — Competitive Intelligence Brief. https://druglandscape.com/ci/methotrexate-6-mercaptopurine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab